Affiliation:
1. Unidad de Microbiología Experimental-Centro de Investigación
2. Servicio de Microbiología, Hospital Universitario La Fe, 46009 Valencia, Spain
3. Division of Infectious Disease, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298-0049
Abstract
ABSTRACT
In a previous study tolerance to amphotericin B (AMB) was found among
Candida parapsilosis
and
C. dubliniensis
strains by seeding the whole volumes of wells used for MIC determinations, and minimum fungicidal concentrations (MFC) for non-
C. albicans Candida
strains were demonstrated to be above the levels safely achievable in serum. As an extension of that study, we performed time-kill assays with 26 blood culture isolates (6
C. albicans
, 5
C. parapsilosis
, 5
C. krusei
, 4 C.
glabrata
, 3
C. lusitaniae
, and 3
C. tropicalis
isolates), 3 oropharyngeal
C. dubliniensis
isolates, 3 AMB-susceptible isolates (ATCC 90028, ATCC 22019, ATCC 6254), and 6 AMB-resistant isolates (ATCC 200955, ATCC 200956, ATCC 200950, ATCC 200951, ATCC 200952, ATCC 200953) using RPMI 1640 medium and 0.12 to 32 μg of AMB per ml and determined the numbers of CFU per milliliter at 0, 2, 4, 8, 12, 24, and 48 h. MFCs and time-kill patterns were species specific (MFCs, ≤1 μg/ml for all
C. dubliniensis
and
C. albicans
isolates except AMB-resistant strain ATCC 200955; MFCs, 2 to >16 μg/ml for the other isolates). The times required to reach the fungicidal endpoint (99.9% killing) at four times the MIC were 2 h for
C. albicans
and
C. dubliniensis
, 16 h for
C. glabrata
, 24 h for
C. parapsilosis
and
C. lusitaniae
, and ≥40 h for
C. tropicalis
and
C. krusei
. The killing rate increased as the AMB concentration was increased up to 2 μg/ml. The highest killing rates were achieved for
C. albicans
,
C. dubliniensis
, and
C. lusitaniae
, while viable
C. tropicalis, C. krusei
, and
C. parapsilosis
cells were present after 48 h (MICs, ≤2 μg/ml) when AMB was used at 2 μg/ml. Time-kill curves and MFCs can detect viable cells after 48 h when AMB is used at ≥2 μg/ml. The failure of AMB treatment could be due to its poor killing activity against some species at the concentrations reached in patients' serum.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology